Novo Nordisk(US:NVO) Prnewswireยท2025-09-05 12:45Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Novo Nordisk made misleading statements regarding its growth potential, particularly concerning the compounded GLP-1 market and the likelihood of patients switching to its branded products [2]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, which led to a significant stock price drop of approximately 21.83%, from $69.00 to $53.94 per share in one day [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].